OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

Core Viewpoint - OpGen, Inc. has received a notice from Nasdaq indicating non-compliance with listing rules due to the failure to file its Quarterly Report on Form 10-Q for the period ended March 31, 2024, which may lead to delisting from Nasdaq [1][2]. Compliance Issues - The company previously received notices for non-compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price of $1.00 per share and Listing Rule 5250(c)(1) for not timely filing its Annual Report on Form 10-K for the period ended December 31, 2023 [2]. - Nasdaq Hearings Panel has granted the company until June 3, 2024, to regain compliance with both the Minimum Bid Price Rule and the Periodic Filing Rule [2]. Current Status - The notice from Nasdaq does not have an immediate effect on the listing or trading of the company's common stock [3]. - The company is actively working to finalize and file the Form 10-Q as soon as possible to regain compliance with Nasdaq Listing Rules [3]. Company Overview - OpGen, Inc. is a precision medicine company focused on molecular diagnostics and bioinformatics to combat infectious diseases, providing solutions that improve patient outcomes and reduce the spread of multidrug-resistant microorganisms [4].